PMID- 31538025
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 10
IP  - 2
DP  - 2019 Mar
TI  - Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event 
      Management.
PG  - 136-153
AB  - Although breast cancer is a heterogeneous disease, approximately 20% to 25% of 
      patients diagnosed with breast cancer have amplification of the HER2 gene. The 
      FDA approval of trastuzumab for the treatment of HER2-positive (HER2+) metastatic 
      breast cancer in 1998 represented a major breakthrough for patients with HER2+ 
      disease. In 2006, the FDA extended its approval for use in the adjuvant setting. 
      In recent years, trials have been conducted to identify the appropriate duration 
      of therapy in combination with chemotherapy. More recently, trials incorporating 
      newer HER2-targeted therapies have been conducted. Some trials have demonstrated 
      the importance of considering neoadjuvant HER2-directed therapies for selected 
      patients with HER2+ disease, highlighting the fact that achieving pathologic 
      complete response has important prognostic implications. In order to continue 
      treatment and optimize patient safety, the effective and timely management of 
      treatment-related adverse events (AEs) is crucial. As they are on the front lines 
      of patient care, advanced practitioners need to be able to assess the clinical 
      implications of recent advances and integrate them into practice. One area of 
      unmet need in the management of metastatic HER2-positive disease is the treatment 
      of brain metastases, with several promising therapies under investigation. Using 
      several case studies as a foundation, this article highlights current and 
      emerging data on HER2-directed therapies, outlines strategies for managing AEs, 
      and reviews the key issues surrounding brain metastases and associated novel 
      therapies under investigation.
FAU - Mahtani, Reshma
AU  - Mahtani R
AD  - Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, 
      Florida, and Los Angeles Cancer Network, Los Angeles, California.
FAU - Hineman, Lisa
AU  - Hineman L
AD  - Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, 
      Florida, and Los Angeles Cancer Network, Los Angeles, California.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190301
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC6750923
EDAT- 2019/09/21 06:00
MHDA- 2019/09/21 06:01
PMCR- 2019/03/01
CRDT- 2019/09/21 06:00
PHST- 2019/09/21 06:00 [entrez]
PHST- 2019/09/21 06:00 [pubmed]
PHST- 2019/09/21 06:01 [medline]
PHST- 2019/03/01 00:00 [pmc-release]
PST - ppublish
SO  - J Adv Pract Oncol. 2019 Mar;10(2):136-153. Epub 2019 Mar 1.